摘要
目的:评价联合运用降脂通脉胶囊治疗血脂异常的临床疗效及安全性。方法:计算机检索维普(VIP)、中国知网(CNKI)、万方(WanFang Data)、中国生物医学文献数据库(CBM)、PubMed、the Cochrane Library、EMbase等收录的有关联合运用降脂通脉胶囊治疗血脂异常的随机对照试验(RCT)。检索时限为建库至2022年9月采用Cochrane评价手册中的偏倚风险评估工具进行评估,并使用RevMan 5.4.1与Stata 14.0软件进行Meta分析,系统评价降脂通脉胶囊对总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、颈动脉内中膜厚度(IMT)及颈动脉斑块积分的影响。结果:共纳入11项RCT,涉及914例血脂异常病人。采用降脂通脉胶囊联合常规西药治疗的试验组TC[MD=-0.69,95%CI(-0.98,-0.40),P<0.00001]、LDL-C[MD=-0.52,95%CI(-0.74,-0.31),P<0.00001]、TG[MD=-0.47,95%CI(-0.67,-0.26),P<0.00001]、IMT[MD=-0.27,95%CI(-0.33,-0.22),P<0.00001]与颈动脉斑块积分[MD=-1.43,95%CI(-2.33,-0.63),P=0.0004]水平较采用常规西药治疗的对照组明显降低,HDL-C[MD=0.20,95%CI(0.07,0.32),P=0.002]水平与临床疗效[OR=3.49,95%CI(2.11,5.76),P<0.00001]较对照组明显提高。两组不良反应发生率比较差异无统计学意义[OR=1.25,95%CI(0.59,2.65),P=0.57]。结论:现有证据表明,加用降脂通脉胶囊治疗血脂异常效果优于单纯西药常规治疗。
Objective:To assess the clinical effectiveness and safety of Jiangzhi Tongmai Capsule for the treatment of dyslipidemia.Methods:VIP,China National Knowledge Infrastructure(CNKI),WanFang Data,China Biology Medicine Disc(CBM),PubMed,the Cochrane Library,and EMbase were searched for randomized controlled trials(RCT)of Jiangzhi Tongmai Capsule for the management of dyslipidemia.The retrieval time limit is from the establishment of the databases to September 2022.The Cochrane systematic review manual bias risk assessment tool was used to evaluate the bias risk of the included study.The Stata 14.0 software was used for Meta analysis.Results:A total of 11 RCT were included,involving 914 cases.Meta-analysis showed that total cholesterol(TC)(MD=-0.69,95%CI-0.98--0.40,P<0.00001),low density lipoprotein cholesterol(LDL-C)(MD=-0.52,95%CI-0.74--0.31,P<0.00001),triglyceride(TG)(MD=-0.47,95%CI-0.67--0.26,P<0.00001),carotid intima-media thickness(IMT)(MD=-0.27,95%CI-0.33--0.22,P<0.00001),and carotid plaque score(MD=-1.43,95%CI-2.33--0.63,P=0.0004)in experimental group were lower than those in control group.The high density lipoprotein cholesterol(HDL-C)(MD=0.20,95%CI 0.07-0.32,P=0.002)and clinical efficacy(OR=3.49,95%CI 2.11-5.76,P<0.00001)in experimental group were higher than those in control group.There was no statistically significant difference in the occurrence of adverse reactions between the experimental and control groups(OR=1.25,95%CI 0.59-2.65,P=0.57).Conclusion:Available evidence indicates that combined application of Jiangzhi Tongmai Capsule is superior to conventional western medicine alone in improving the clinical efficacy of dyslipidemia.
作者
赵哲俊
孙元隆
王肖龙
李琳
黄程新
贾美君
ZHAO Zhejun;SUN Yuanlong;WANG Xiaolong;LI Lin;HUANG Chengxin;JIA Meijun(Shuguang Hospital of Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China)
出处
《中西医结合心脑血管病杂志》
2024年第7期1204-1212,共9页
Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
基金
国家自然科学青年基金项目(No.81603381)
第七批全国老中医药专家学术经验继承工作项目,编号:国中医药人教函〔2022〕76号
上海市临床重点专科项目(No.shslczdzk05301)
国家自然科学基金面上项目(No.82174152)。
